Zydelig (idelalisib tablets - Gilead) — Cigna
Small Lymphocytic Lymphoma
Initial criteria
- Patient is age ≥ 18 years; AND
- Patient has tried at least one Bruton tyrosine kinase inhibitor (e.g., Imbruvica [ibrutinib], Brukinsa [zanubrutinib], Calquence [acalabrutinib], or Jaypirca [pirtobrutinib]); AND
- Patient has tried at least one B-cell lymphoma 2 inhibitor (e.g., Venclexta [venetoclax]).
Approval duration
1 year